Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Explore linked clinical trials.5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents | Body Weight, Body Weight Changes, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Pediatric Obesity, Signs and Symptoms, Weight Loss, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 1 | 2026-07-30 | NCT07693426 | |
| A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Not yet recruiting | Phase 1 | 2026-04-08 | NCT07518121 | |
| The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT) | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 2 / Phase 3 | 2026-01-30 | NCT06921486 | |
| The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity（SPARKLE） | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 2 | 2025-12-02 | NCT07114419 | |
| Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Not yet recruiting | Phase 3 | 2025-03-28 | NCT06900075 |